

Federico Salomone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/126510/publications.pdf>

Version: 2024-02-01

47
papers

2,167
citations

218381

26
h-index

253896

43
g-index

47
all docs

47
docs citations

47
times ranked

3958
citing authors

#	ARTICLE	IF	CITATIONS
1	Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives. <i>Liver International</i> , 2016, 36, 5-20.	1.9	203
2	The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. <i>Liver International</i> , 2017, 37, 936-949.	1.9	178
3	The interaction of metabolic factors with HCV infection: Does it matter?. <i>Journal of Hepatology</i> , 2012, 56, S56-S65.	1.8	152
4	Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies. <i>Clinical Nutrition</i> , 2016, 35, 1269-1281.	2.3	140
5	Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. <i>Translational Research</i> , 2012, 159, 477-486.	2.2	104
6	Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 392-407.	1.4	100
7	Molecular Bases Underlying the Hepatoprotective Effects of Coffee. <i>Nutrients</i> , 2017, 9, 85.	1.7	78
8	Efficacy of adipose tissue-mesenchymal stem cell transplantation in rats with acetaminophen liver injury. <i>Stem Cell Research</i> , 2013, 11, 1037-1044.	0.3	75
9	Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. <i>Translational Research</i> , 2016, 167, 116-124.	2.2	73
10	Silibinin Restores NAD+ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver. <i>Nutrients</i> , 2017, 9, 1086.	1.7	72
11	Chronic hepatitis C: This and the new era of treatment. <i>World Journal of Hepatology</i> , 2016, 8, 92.	0.8	69
12	Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2016, 63, 107-116.	3.6	67
13	Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population. <i>Translational Research</i> , 2015, 165, 428-436.	2.2	65
14	Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice. <i>Cardiovascular Diabetology</i> , 2011, 10, 62.	2.7	64
15	Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis. <i>Digestive and Liver Disease</i> , 2012, 44, 334-342.	0.4	63
16	Moro orange juice prevents fatty liver in mice. <i>World Journal of Gastroenterology</i> , 2012, 18, 3862.	1.4	62
17	Coffee enhances the expression of chaperones and antioxidant proteins in rats with nonalcoholic fatty liver disease. <i>Translational Research</i> , 2014, 163, 593-602.	2.2	57
18	Unconjugated bilirubin, a potent endogenous antioxidant, is decreased in patients with non-alcoholic steatohepatitis and advanced fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1202-1208.	1.4	55

#	ARTICLE	IF	CITATIONS
19	Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2019, 51, 1698-1705.	0.4	52
20	Nonalcoholic fatty liver disease: The hepatic trigger of the metabolic syndrome. <i>Journal of Hepatology</i> , 2010, 53, 1146-1147.	1.8	48
21	Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease. <i>Liver International</i> , 2014, 34, e128-35.	1.9	48
22	Coffee Consumption and Risk of Biliary Tract Cancers and Liver Cancer: A Dose-Response Meta-Analysis of Prospective Cohort Studies. <i>Nutrients</i> , 2017, 9, 950.	1.7	43
23	Coffee prevents fatty liver disease induced by a high-fat diet by modulating pathways of the gut-liver axis. <i>Journal of Nutritional Science</i> , 2019, 8, e15.	0.7	42
24	Higher phenolic acid intake independently associates with lower prevalence of insulin resistance and non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2020, 2, 100069.	2.6	38
25	Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease: Evidence and perspectives. <i>Liver International</i> , 2020, 40, 1262-1268.	1.9	34
26	Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 311-317.e1.	2.4	30
27	Simple Scores of Fibrosis and Mortality in Patients with NAFLD: A Systematic Review with Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2018, 7, 219.	1.0	28
28	HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas. <i>Acta Diabetologica</i> , 2011, 48, 337-343.	1.2	22
29	Coffee Restores Expression of lncRNAs Involved in Steatosis and Fibrosis in a Mouse Model of NAFLD. <i>Nutrients</i> , 2021, 13, 2952.	1.7	19
30	Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis. <i>Liver International</i> , 2020, 40, 2820-2827.	1.9	17
31	Effects of intragastric balloon in patients with nonalcoholic fatty liver disease and advanced fibrosis. <i>Liver International</i> , 2021, 41, 2112-2116.	1.9	14
32	Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature. <i>Current Molecular Medicine</i> , 2016, 16, 721-737.	0.6	13
33	Hepatitis C virus eradication by direct antiviral agents improves glucose tolerance and reduces post-load insulin resistance in nondiabetic patients with genotype 1. <i>Liver International</i> , 2018, 38, 1206-1211.	1.9	11
34	Protective role of soluble receptor for advanced glycation end-products in patients with non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2017, 49, 523-529.	0.4	9
35	Anthocyanins-based drugs for colon cancer treatment: the nutritionist's point of view. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 431-432.	1.1	6
36	Treating fatty liver for the prevention of cardiovascular diseases. <i>Hepatology</i> , 2010, 52, 1174-1175.	3.6	4

#	ARTICLE	IF	CITATIONS
37	Targeting heme oxygenase/adiponectin axis for chronic hepatitis C treatment. <i>Hepatology</i> , 2010, 52, 801-801.	3.6	3
38	Clinical Challenges and Images in GI. <i>Gastroenterology</i> , 2008, 134, 920-1276.	0.6	2
39	Intestinal HCV-Related Mixed Cryoglobulinemia. <i>Gastroenterology</i> , 2010, 138, e9-e10.	0.6	2
40	Insulin resistance links nonalcoholic fatty liver to cardiovascular diseases. <i>Hepatology</i> , 2011, 53, 1785-1786.	3.6	2
41	P840 ALTERATION IN LIPID METABOLISM AFTER AN ORAL FAT LOAD IN PATIENTS WITH NAFLD. <i>Journal of Hepatology</i> , 2014, 60, S352.	1.8	1
42	Non-Alcoholic Steatohepatitis: Pathogenesis and Clinical Management. <i>BioMed Research International</i> , 2015, 2015, 1-1.	0.9	1
43	High Intake of Phenolic Acids Is Associated With Reduced Risk of Colorectal Adenomas Among Smokers. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1893-1895.e3.	2.4	1
44	799 SILYBIN IMPROVES LIVER INJURY IN EXPERIMENTAL NAFLD. <i>Journal of Hepatology</i> , 2010, 52, S310.	1.8	0
45	Corrigendum to "Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis" [Dig. Liver Dis. 44 (2012) 334-342]. <i>Digestive and Liver Disease</i> , 2012, 44, 709.	0.4	0
46	Silibinin Protects Hepatocytes from Lipotoxicity by Inducing AMPK Phosphorylation and miRNA130a Expression. <i>FASEB Journal</i> , 2015, 29, 885.18.	0.2	0
47	Beneficial Effects of Silybin Treatment After Viral Eradication in Patients With HCV-Related Advanced Chronic Liver Disease: A Pilot Study. <i>Frontiers in Pharmacology</i> , 2022, 13, 824879.	1.6	0